Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Celldex Therapeutics but reduced the price target from $67 to $61. This indicates a slightly less optimistic outlook from the analyst, which could lead to minor downward pressure on the stock in the short term.
Cantor Fitzgerald analyst Kristen Kluska maintained an 'Overweight' rating on Celldex Therapeutics, signaling continued confidence in the company's long-term prospects. However, the simultaneous reduction of the price target from $67 to $61 suggests a recalibration of near-term valuation expectations, possibly due to market conditions, competitive landscape, or updated financial models. This move could create short-term selling pressure on CLDX as some investors might interpret the lower price target as a less bullish signal. For traders, this presents a potential opportunity for a minor dip, while long-term investors might view it as a slight adjustment rather than a fundamental change in the company's outlook.